Ribavirin
What's New
Last Posted: Jan 16, 2024
- The severity of depressive symptoms as an independent predictor of Sustained Virological Response during treatment for hepatitis C with pegylated interferon-?2a and oral ribavirin.
Tomasz Paw?owski, et al. Psychosomatic medicine 2024 0 - Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon.
Tropical biomedicine 2023 0 (3) 331-336 - A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.
Xiaoting Li, et al. Discovery medicine 2023 0 (178) 868-876 - Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Pooja Devan, et al. Viruses 2023 0 (7) - Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Doaa Mohamed Abdelnajid, et al. Medicine 2023 0 (28) e34125 - Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Yu Jun Wong, et al. Hepatology international 2023 0 - Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy.
Nakamoto Shingo, et al. International journal of medical sciences 2017 0 (11) 1088-1093 - Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E, et al. HIV medicine 2017 0 (3) 227-237 - Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui Lamis R, et al. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2017 0 (19) 1533-1540 - Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
Omar H, et al. Alimentary pharmacology & therapeutics 2017 0 (3) 421-431
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 19, 2024
- Content source: